HUP0204159A2 - Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására - Google Patents

Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására

Info

Publication number
HUP0204159A2
HUP0204159A2 HU0204159A HUP0204159A HUP0204159A2 HU P0204159 A2 HUP0204159 A2 HU P0204159A2 HU 0204159 A HU0204159 A HU 0204159A HU P0204159 A HUP0204159 A HU P0204159A HU P0204159 A2 HUP0204159 A2 HU P0204159A2
Authority
HU
Hungary
Prior art keywords
preparation
compositions
erectile dysfunction
prostaglandin
treatment
Prior art date
Application number
HU0204159A
Other languages
English (en)
Inventor
Nadir Buyuktimkin
Servet Buyuktimkin
James Yeager
Original Assignee
Nexmed Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23909154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204159(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexmed Holdings, Inc. filed Critical Nexmed Holdings, Inc.
Publication of HUP0204159A2 publication Critical patent/HUP0204159A2/hu
Publication of HUP0204159A3 publication Critical patent/HUP0204159A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány az alábbi anyagok alkalmazása erekciózavar kezeléséreszolgáló gyógyászati készítmény előállítására ilyen kezelésre szorulópáciensek számára, melynek során a gyógyászati készítményt a páciensfossa naviculárisába juttatják: a) prosztaglandin b) penetrációtelősegítő szer, amely az alábbiakat tartalmazó csoport tagja: alkil-2-(N,N-diszubsztituált amino)-alkanoát, (N,N-diszubsztituált)-alkanol-alkanoát, ezek gyógyászatilag alkalmazható sói és keverékei; c)poliszacharid gumi; d) lipofil vegyület, amely az alábbiakattartalmazó csoport tagja: alifás 1-8 szénatomos alkohol, alifás 8-30szénatomszámú észter és ezek keverékei; és e) savas pufferrendszer. Atalálmány tárgyát képezi továbbá a fenti alkalmazás segítségévelelőállított készítmény is. Ó
HU0204159A 2000-01-10 2001-01-10 Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction HUP0204159A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/480,738 US6323241B1 (en) 2000-01-10 2000-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction
PCT/US2001/000852 WO2001051053A1 (en) 2000-01-10 2001-01-10 Prostaglandin compositions and methods of treatment for male erectile dysfunction

Publications (2)

Publication Number Publication Date
HUP0204159A2 true HUP0204159A2 (hu) 2003-04-28
HUP0204159A3 HUP0204159A3 (en) 2005-03-29

Family

ID=23909154

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204159A HUP0204159A3 (en) 2000-01-10 2001-01-10 Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction

Country Status (20)

Country Link
US (1) US6323241B1 (hu)
EP (1) EP1255552B1 (hu)
JP (2) JP2003519657A (hu)
KR (1) KR100614361B1 (hu)
CN (1) CN1394140A (hu)
AT (1) ATE290383T1 (hu)
AU (1) AU760576C (hu)
BE (1) BE2014C001I2 (hu)
BR (1) BR0107478A (hu)
CA (1) CA2395217C (hu)
DE (1) DE60109274T2 (hu)
ES (1) ES2236245T3 (hu)
HK (1) HK1047700B (hu)
HU (1) HUP0204159A3 (hu)
IL (2) IL150306A0 (hu)
MX (1) MXPA02006758A (hu)
PT (1) PT1255552E (hu)
TR (1) TR200201769T2 (hu)
WO (1) WO2001051053A1 (hu)
ZA (1) ZA200205433B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003063776A2 (en) 2002-01-25 2003-08-07 Modular Properties Ltd Methods and compositions for treating male erectile dysfunction
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
IL162154A0 (en) * 2002-02-15 2005-11-20 Nexmed Holdings Inc Prostagandin composition for the treatment of erectile dysfunction
KR20050057245A (ko) * 2002-09-06 2005-06-16 넥스메드 홀딩스 인코포레이티드 남성 발기 부전을 치료하는 방법
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20040241243A1 (en) * 2003-03-21 2004-12-02 Nexmed (Holdings) Inc. Angiogenesis promotion by prostaglandin compositions and methods
WO2004084878A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Compositions and methods for treatment of premature ejaculation
WO2004084908A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
KR20050119187A (ko) * 2003-04-02 2005-12-20 넥스메드 홀딩스 인코포레이티드 프로스타글란딘 조성물 및 이의 혈관연축 치료용 용도
US20050159985A1 (en) * 2003-11-21 2005-07-21 Bertram Carl T. System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US7655659B2 (en) * 2004-08-19 2010-02-02 Applied Genetics Incorporated Dermatics Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
KR102004552B1 (ko) * 2010-12-02 2019-10-01 넥스메드 홀딩스 인코포레이티드 도데실 2-(n,n-다이메틸아미노)-프로피오네이트의 활성 거울상체
CA2838109C (en) 2011-04-07 2020-06-09 Nexmed Holdings, Inc. Topical semisolid prostaglandin e1 composition for treating raynaud's disease
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
CA2974113A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
EP3266458A1 (en) 2016-07-05 2018-01-10 Fagron B.V. Method and composition and kit for treating erectile dysfunction
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
BE790840A (fr) 1971-11-01 1973-04-30 Upjohn Co Solutions de medicaments instables et leur preparation
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
NZ270871A (en) 1990-04-25 1999-05-28 Vivus Inc Method for treating erectile dysfunction
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
TR199700930T2 (xx) 1995-03-14 1998-07-21 Vivus Incorporated Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
WO1999002147A1 (en) * 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
CA2305394C (en) * 1997-10-28 2006-12-12 Vivus, Incorporated Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6102849A (en) 1999-04-03 2000-08-15 Hakac; John R. Non-surgical penile prosthesis

Also Published As

Publication number Publication date
AU760576C (en) 2004-04-08
KR100614361B1 (ko) 2006-08-18
IL150306A (en) 2007-06-03
CA2395217C (en) 2004-10-26
ATE290383T1 (de) 2005-03-15
US6323241B1 (en) 2001-11-27
MXPA02006758A (es) 2008-09-12
CN1394140A (zh) 2003-01-29
HK1047700A1 (en) 2003-03-07
JP2007302690A (ja) 2007-11-22
JP2003519657A (ja) 2003-06-24
PT1255552E (pt) 2005-06-30
AU760576B2 (en) 2003-05-15
ZA200205433B (en) 2003-11-26
HUP0204159A3 (en) 2005-03-29
ES2236245T3 (es) 2005-07-16
DE60109274D1 (de) 2005-04-14
EP1255552B1 (en) 2005-03-09
IL150306A0 (en) 2002-12-01
TR200201769T2 (tr) 2002-11-21
BR0107478A (pt) 2002-09-03
KR20020073498A (ko) 2002-09-26
CA2395217A1 (en) 2001-07-19
AU2934901A (en) 2001-07-24
BE2014C001I2 (hu) 2020-01-30
HK1047700B (zh) 2005-05-27
WO2001051053A1 (en) 2001-07-19
DE60109274T2 (de) 2006-02-09
EP1255552A1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
HUP0204159A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
HUP0401816A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
HUP0201145A2 (hu) Prosztaglandin E1 leadására szolgáló helyileg adagolandó készítmények
DE69532678D1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
EP1243269A3 (en) Opioid formulations having extended controlled release
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
AR065827A2 (es) Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina, composicion farmaceutica, procedimiento y preparacion y su uso en terapia
CO4750658A1 (es) Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
ATE173923T1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
US4892877A (en) Antitussive liquid compositions containing phenol
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
JP2005187328A (ja) イブプロフェン含有解熱鎮痛組成物、及び感冒薬
JPS6411613B2 (hu)
JP2548686B2 (ja) 外用薬剤組成物

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished
NF4A Restoration of patent protection
GB9A Succession in title

Owner name: FERRING INTERNATIONAL CENTER S.A., CH

Free format text: FORMER OWNER(S): NEXMED HOLDINGS, INC., US